SCHEMBL793299

SCHEMBL793299

O=S(=O)(Nc1cccc(-c2nnn[nH]2)c1)c1ccc2ccccc2c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PFKFB3 Q16875 2/20 0.65
LMNA P02545 2/20 0.55
HTT P42858 2/20 0.55
MAPT P10636 1/20 0.55
KMT2A Q03164 2/20 0.54
MEN1 O00255 1/20 0.54
GGPS1 O95749 1/20 0.50
PKM P14618 2/20 0.49
PKLR P30613 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PLAU P00749 1/20 0.48
MMP2 P08253 1/20 0.48
MMP9 P14780 1/20 0.48
MMP8 P22894 1/20 0.48
MMP13 P45452 1/20 0.48
ATM Q13315 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
PFKFB4 Q16877 1/20 0.47
TSHR P16473 1/20 0.47
GHSR Q92847 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6078400 0.87 PFKFB3 (0.51) PFKFB3LMNAHTTMAPTMMP2
SCHEMBL794304 0.87 PFKFB3 (0.63) PFKFB3LMNAHTTMAPTKMT2A
SCHEMBL27943370 0.87 MMP2 (0.59) PFKFB3LMNAHTTMAPTKMT2A
SCHEMBL793607 0.86 PFKFB4 (0.64) PFKFB3LMNAHTTKMT2AMEN1
SCHEMBL793433 0.81 PFKFB4 (0.67) PFKFB3LMNAHTTMAPTPKM
SCHEMBL794177 0.80 CA12 (0.50) PFKFB3LMNAHTTMAPTKMT2A
SCHEMBL806077 0.80 PFKFB3 (0.67) PFKFB3MMP2MMP9MMP8MMP13
SCHEMBL793332 0.80 PFKFB3 (0.55) PFKFB3MMP2MMP9MMP8MMP13
SCHEMBL792878 0.80 PFKFB3 (0.67) PFKFB3MMP2MMP9MMP8MMP13
SCHEMBL794341 0.80 PFKFB4 (0.54) PFKFB3MMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2616450-A2 SULFONAMIDE COMPOUNDS Kancera AB (SE) 2013-07-24 EP claimed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
CN-113396145-A PFKFB3 inhibitors and uses thereof 盖罗发现有限责任公司 2021-09-14 CN disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-9233946-B2 Sulfonamide compounds KANCERA AB (SE) 2016-01-12 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
US-20130172339-A1 SULFONAMIDE COMPOUNDS KANCERA AB (SE) 2013-07-04 US disclosed
WO-2012035171-A2 NEW COMPOUNDS KANCERA AB (SE) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 PFKFB3 1/4885LMNA 4383/4885HTT 1690/4885
US-20130172339-A1 SULFONAMIDE COMPOUNDS SULT1A1, STS, ARSA PFKFB3 952/4885LMNA 1654/4885HTT 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.